The Cancer Act that was signed by President Nixon in December 1971 had a mandate “to support research and the application of the results of research, to reduce the incidence, morbidity and mortality from cancer.” It has succeeded in many of these aims, as this personal account testifies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The American Presidency Project (Peters, G. & Woolley, J. T. Eds). Richard Nixon: Remarks on Signing the National Cancer Act of 1971 [online], (1971).
Watson, J. D. To fight cancer, know the enemy. The New York Times (New York) A29 (6 August 2009).
Greenberg, D. S. & Randal, J. E. Waging the wrong war on cancer. Washington Post (Washington) c1–c4 (1 May 1977).
Leaf, C. Why we're losing the war on cancer [and how to win it] [Avastin, Erbitux, Gleevec ... The new wonder drugs might make you think we're finally beating this dreaded scourge. We're not. Here's how to turn the fight around.] Fortune Magazine 77–92 (22 March 2004).
National Center for Health Statistics, Centers for Disease Control and Prevention. US Mortality Data 1960–2006 US Mortality Volumes 1930–1959 (2009).
Byers, T. E. in Cancer: Principles & Practices of Oncology 9th edn Ch. 24 (eds DeVita, V. Jr, Lawrence, T. S. & Rosenberg, S. A.) 261–268 (Wolters Kluwer, Lippincott Williams & Wilkins, 2011).
Byers, T. et al. A midpoint assessment of the American Cancer Society challenge goal to halve the U. S. cancer mortality rates between the years 1990 and 2015. Cancer 107, 396–405 (2006).
Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2011).
Rosenberg, S. A. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. Nat. Rev. Clin. Oncol. 8, 577–585 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
DeVita, V. A personal note—40 years after the signing of the Cancer Act. Nat Rev Clin Oncol 8, 693–694 (2011). https://doi.org/10.1038/nrclinonc.2011.168
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.168
